Belatacept

Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,^[2] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant^[3] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.^{[medical citation needed]}

Belatacept

Clinical data
Trade names	Nulojix
AHFS/Drugs.com	Monograph
MedlinePlus	a606016
License data	EU EMA: by INN US DailyMed: Belatacept US FDA: Belatacept
Pregnancy category	AU: C
Routes of administration	Intravenous
ATC code	L04AA28 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: WARNING[1]Rx-only EU: Rx-only
Identifiers
CAS Number	706808-37-9 Y
DrugBank	DB06681 Y
ChemSpider	None
UNII	E3B2GI648A
KEGG	D03222
NY (what is this?)  (verify)

Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011.^[4]

References

1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
2. "Healthvalue.net: CTLA-4 Strategies". Archived from the original on 5 December 2008. Retrieved 2008-10-24.
3. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. (January 2016). "Belatacept and Long-Term Outcomes in Kidney Transplantation". The New England Journal of Medicine. 374 (4): 333–43. doi:10.1056/NEJMoa1506027. hdl:2445/178537. PMID 26816011. S2CID 35661528.
4. "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. Archived from the original on 19 June 2011. Retrieved 2011-06-16.

External links

• "Belatacept". Drug Information Portal. U.S. National Library of Medicine.